ID   MCF/MX
AC   CVCL_4Y47
SY   MCF-7/MX; MCF-7/mtxR
DR   cancercelllines; CVCL_4Y47
DR   Wikidata; Q54904412
RX   PubMed=1358431;
RX   PubMed=7664272;
RX   PubMed=9865745;
RX   PubMed=11559526;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0031 ! MCF-7
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 05-10-23; Version: 13
//
RX   PubMed=1358431;
RA   Nakagawa M., Schneider E., Dixon K.H., Horton J.K., Kelley K.,
RA   Morrow C., Cowan K.H.;
RT   "Reduced intracellular drug accumulation in the absence of
RT   P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human
RT   MCF-7 breast cancer cells.";
RL   Cancer Res. 52:6175-6181(1992).
//
RX   PubMed=7664272;
RA   Yang C.-H.J., Horton J.K., Cowan K.H., Schneider E.;
RT   "Cross-resistance to camptothecin analogues in a
RT   mitoxantrone-resistant human breast carcinoma cell line is not due to
RT   DNA topoisomerase I alterations.";
RL   Cancer Res. 55:4004-4009(1995).
//
RX   PubMed=9865745;
RA   Rabindran S.K., He H.-Y., Singh M., Brown E., Collins K.I., Annable T.,
RA   Greenberger L.M.;
RT   "Reversal of a novel multidrug resistance mechanism in human colon
RT   carcinoma cells by fumitremorgin C.";
RL   Cancer Res. 58:5850-5858(1998).
//
RX   PubMed=11559526;
RA   Honjo Y., Hrycyna C.A., Yan Q.-W., Medina-Perez W.Y., Robey R.W.,
RA   van de Laar A., Litman T., Dean M., Bates S.E.;
RT   "Acquired mutations in the MXR/BCRP/ABCP gene alter substrate
RT   specificity in MXR/BCRP/ABCP-overexpressing cells.";
RL   Cancer Res. 61:6635-6639(2001).
//